Human Leukocyte Antigen (HLA) testing is useful in the clinical work-up of coeliac disease (CD), with high negative but low positive predictive value. We construct a genomic risk score (GRS) using HLA risk loci to improve CD prediction and guide exclusion criteria.
Introduction
Coeliac disease (CD) is a chronic immune disease characterised by small intestine damage resulting from ingestion of gluten, the alcohol insoluble protein in wheat, barley and rye [1] . CD is a common disease, with a prevalence of 0.5-2% in Caucasian and Middle Eastern populations [2] [3] [4] . The current diagnostic gold-standard for CD is the demonstration of characteristic small intestinal inflammation and damage while on a gluten-containing diet [5] . Intestinal biopsies are obtained by upper gastrointestinal endoscopy, a resource intensive, invasive and inconvenient process [6] . While CDspecific serotyping of antibody markers is a strong positive predictor of disease, these tests are inaccurate in patients already on a gluten-free diet and patients with other conditions such as liver disease, inflammatory bowel disease and type-1 diabetes [7] . Alternative, non-invasive, risk stratification strategies are desired to reduce unnecessary endoscopies and improve the overall effectiveness of CD investigation [3] .
One increasingly adopted strategy involves human leukocyte antigen (HLA) typing based on the exceptionally strong association of three major susceptibility alleles, HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*03:02 with CD [8] . Over 99% of individuals with CD carry these risk alleles as part of the DQ2.5 (HLA-DQA1*05, HLA-DQB1*02), DQ2.2 (HLA-DQA1*02, HLA-DQB1*02), DQ7.5( HLA-DQA1*05 without HLA-DQB1*02) or DQ8 (HLA-DQB1*03:02) genotypes [9] . HLA genotyping, as currently used, has limited predictive value for CD due to the high population frequency of these susceptibility genotypes (30-60%) [10, 11] . Thus, while HLA typing alone cannot yield a diagnosis, the test is useful in selected clinical situations, such as assessing individuals already on a gluten-free diet [12] . In these scenarios, the strong negative predictive value of genetic testing can be used to confidently exclude a diagnosis of CD [8] . HLA genotyping is also valuable to help identify high-risk individuals, such as first-degree relatives of CD patients, where prevalence of disease is approximately 10% [8, 13] .
While HLA typing is primarily used for exclusion, whereby those at 'low' risk (DQ7.5 or DQX) are excluded from diagnostic follow-up [6] , there is evidence that this approach may not have captured the diversity in the relative risk of HLA genotypes. Firstly, recent clinical guidelines recommend further refinement of HLA genotype groupings into six categories based on observed relative risk, with the intent of more fine-grained risk estimates of high risk individuals [8] . Secondly, interactions between HLA haplotypes in CD, particularly the DQ2.2. and DQ7.5 haplotypes, were found to increase disease risk and better explain phenotypic variance [14, 15] . Thirdly, a logistic regression using a reduced set of HLA tag SNPs improved prediction of disease compared with coarse stratification, although this analysis did not account for DQ7.5 attributed risk [16] . These insights suggest that more nuanced stratification of risk HLA-DQ genotypes could be used to more effectively capture genetic risk.
To identify additional genomic variants that modulate CD risk, multiple groups have explored the use of loci outside of the HLA region by analysing genome-wide association studies (GWAS). Romanos et al. demonstrated that the addition of 57 non-HLA single nucleotide polymorphisms (SNPs) as part of a genomic risk score (GRS) could improve patient stratification over HLA genotype alone [17] .
Abraham et al., using GWAS data of five European populations, employed penalised regression models to develop a GRS using 228 SNPs capable of further improved patient stratification [16] .
While these models represent the state-of-the-art for genomic prediction of CD, their role and the role of non-HLA genetic information in clinical practice is not yet well established, nor is this type of data routinely collected.
Here, we sought to determine whether the use of state-of-the-art statistical methods could improve prediction of CD with HLA genotypes using only HLA genotypes which are currently clinically collected. Using five European CD case-control GWAS datasets, we demonstrate that HLA-DQ genotype stratification has much greater predictive performance than previously attributed. By conditioning on this risk score, we identify two novel risk alleles, DQ6.2 and DQ7.3, in the UK2 cohort that show significant, replicating interaction effects with DQ2.5. Integrating these novel interactions into our risk score significantly improves risk prediction. Furthermore, we demonstrate that this model can be implemented using only six HLA tagging SNPs. Finally, we assess the impact of shifting the CD exclusionary criteria, demonstrating that it is possible to double the number of individuals excluded via genetic testing, with minimal impact on negative predictive value.
Methods

Genotype and Phenotype Data
Five European CD case and control datasets were used in this analysis from four populations: United Kingdom (UK1, UK2), Finland (FIN), Italy (IT) and the Netherlands (NL) ( Table 1) . Details regarding collection and quality control of these datasets have been described previously [18] . Previous analysis indicates population structure does not play a role in the predictive capacity of models built on these cohorts [16, 18] . Existing risk prediction models HLA genotypes were grouped to match previously described approaches for HLA based risk stratification (Supplementary Table 4 ). The Romanos ( ) [17] and Tye-Din ( ) [8] Using to denote the genotype of the HLA-DQA1/DQB1 locus, and to denote the binary phenotype, the models can be expressed as where ∈ {0,1,2}. This model is expanded to also including an interaction term
where N is a dosage-encoded risk haplotype. We used a likelihood ratio test to compare the fit of models given by Equation 1 and 2 to assess the statistical significance of the interaction, with the test statistic following a + distribution with 1 degrees of freedom. We only consider interactions where the common haplotype and its interaction with a known risk haplotype both have an allele frequency of at least 1% in the discovery (UK2) population, leading to 15 independent tests in total.
Further details in Supplementary Methods.
Identification of HLA haplotype SNP tags
SNP tags [20] were identified for all relevant haplotypes using the T1DGC and 1000 Genomes EUR
populations (Supplementary Methods). The best performing available tags are detailed in
Supplementary 
Measures of Predictive Performance
AUC values were used as the primary measure to quantify predictive performance of all models.
Significance of the AUC differences was evaluated using DeLong's test for paired ROC curves (calculated using the R package pROC [22] ).
Data Visualisation
All plots were derived using R (version 3.3.2) [23] using the package ggplot2 [24] .
Results
Coeliac disease risk estimates from known risk haplotypes can achieve predictive power greater than previously indicated
The model [17] has previously been used as the HLA-attributed risk prediction baseline against which novel GRS models are compared [16, 17] . Examining the distribution of risk across each of the As these results suggest that stratification of patients using the model may not accurately represent HLA mediated risk, we constructed a risk score, $% , using data from the UK2 population. Predictive performance of this model was assessed in 4 independent validation populations and a combined validation population alongside predictive performance of two previously reported HLA models, and [8] , and a state-of-the-art CD genomic risk score In all populations, the $% and ++, models performed equivalently and significantly outperformed all other models. However, on the combination of all four test cohort, the increased performance of ++, was significant ( : 0.874 vs 0.880 for $%, and ++,, = 0.0077).
The performance of the model was much lower (~5%) than all other models in each of the validation populations. The model, recently recommended for clinical practice, performed only marginally worse than the best performing models (~2%). While the overall AUCs of the SNP-based ++, and HLA haplotype based $% were almost identical, differences could be observed between the shapes of ROC curves ( Figure 2B-E Figure 2) . (bottom half). Each analysis is further separated into the discovery phase from the UK2 dataset, and the replication results from all remaining cohorts combined. -log10(P) indicates the -log10(P) and OR is the odds ratio (and confidence interval).
found to decrease risk when observed with the DQ2.5 haplotype (OR=0.13 in UK2, OR=-0.47 in validation). These modulating effects could also be observed in each of the 4 validation populations ( Figure 3A) . Interestingly, DQ7.3 also showed significant additive in both the UK2 discovery and combined validation cohorts ( Figure 3B ). To ensure that the results observed in this work were not driven by imputation error, we identified a set of six SNPs that could be used to establish the presence of HLA risk haplotypes and used these to re-implement the $& model .
The predictive performance of the $& model derived from SNP calls was not statistically different to the haplotypes determined from imputed HLA genotype, in all populations CD screening exclusionary criteria may be modified to improve predictive value using the $& model
The improved risk stratification of the $& model offers an opportunity to re-examine the existing exclusionary criteria used in CD genetic testing to determine whether the high negative predictive value (NPV) can be maintained while improving positive predictive values (PPV). As the three lowest risk haplotypes in the 17 model correspond to the existing exclusionary criteria, we consider the The impact of altering the exclusion criteria on the trade-off between PPV and NPV at a CD prevalence of 1% (approximate frequency in the general population) and 10% (approximate frequency in first degree relatives) is shown in Figure 4 . At a population frequency of 1% ( Figure   4A ), a mean NPV above 0.999 can be maintained even if the 6 lowest HLA risk genotypes per the $& model are treated as negative for CD. In contrast, PPV increased across all cohorts from a mean PPV of 1.9% for the "No DQ2/DQ8" exclusionary criteria to 3.3% for the 6 categories with the lowest CD-risk according to $& . A similar effect is observed at a CD prevalence of 10% ( Figure   4B ), where the usage of these 6 categories as an exclusion cut-off yields PPV improvement from 17.5% to 27.1% while maintaining NPV above 99%. Such an increase in PPV has potential to reduce the number of patients requiring diagnostic follow-up when screening at-risk groups.
Discussion
Despite the high positive predictive value of serological testing and the high negative predictive value of HLA genotyping, biopsy via upper gastrointestinal endoscopy, a resource intensive, invasive and inconvenient process, remains the gold standard for diagnosis of CD. There is a need for improved risk stratification strategies to reduce unnecessary endoscopies and improve the efficiency of CD investigation, particularly in the screening of high-risk, asymptomatic individuals. This work demonstrates that the application of genomic risk score frameworks using only HLA risk haplotypes leads to a predictive performance that significantly outperforms current HLA stratification approaches and can be used to help further uncover the genetic basis of this condition.
A potential clinical impact of this research is the modification of the exclusionary criteria for CD when using genetic testing as a screening tool, especially for children at high risk for CD due to family history, but who are currently asymptomatic. For this at-risk group, recent European guidelines recommend an HLA testing as an initial screening test [26] . If we tested 100,000
individuals from this high-risk group and incorporated DQ8/DQ7.5, DQ2.2/DQX and DQ8/X genotypes into the exclusionary criteria, we would correctly exclude 64,279 individuals from a CD diagnosis and hence from biopsy, a further 21,249 individuals compared to the 43,030 using the current threshold (Supplementary Table 12 ). Similar increases in the number of true-negative diagnoses are observed with a population prevealance of 1% (70,706 up from 47,333) (Supplementary Table 12 ). While this shift in exclusionary criteria leads to a small increase in the false positive rate, this may be allieviated further monitoring or serological testing. As with varying the inclusion criteria for serology testing [26] , further studies need to be conducted to better quantify the impact of any changes .
By conditioning on the $% model, two novel haplotypes which modulate HLA risk may be identified which significantly improve HLA mediated prediction, and taken with previous studies provide further evidence that non-additive interactions between HLA loci may be common. While additional independent SNPs within the HLA region have been previously identified by CD GWAS [27] , no study has translated this signal to associations with DQ6.2 or DQ7.3 .The effect size of these variants in their interaction with DQ2.5 in the validation cohort are more extreme than the strongest reported non-HLA variants. Their impact on risk prediction is significant and indicates their potential importance for understanding the underpinnings of CD. We note however that there is clear variability across the different populations, especially for DQ6.2, indicating the potential for other modifiers of this relationship.
Interestingly, we found that DQ7.3 was significant in discovery and replication cohorts when analysed univariately. We believe this haplotype may have been missed in previous studies due the typing resolution and sample size needed to detect the effects of this relatively rare haplotype. Future study of the mechanism by which these interactions modulate DQ2.5 risk will help inform how HLA alleles mediate disease predisposition on the molecular level.
The ability to implement the $& model using either HLA genotype or SNP-tags indicates that it may be a more easily translatable alternative to existing GRS approaches given that HLA genotyping is already in use in routine CD diagnosis. Exclusionary typing for CD is now one of the most common genetic tests performed each year in Australia [8] , and if this typing has already been performed, the $& model may be implemented at no additional expense, to better understand patient risk. An interesting area of relevant research is point-of-care SNP genotyping [28, 29] , where the small panel of SNPs, combined with point-of-care serological tools [30] , may provide a pathway towards immediate, confident CD exclusion at a low cost in the clinical setting.
The HLA-only $& model performs equivalently to state-of-the-art genomic prediction models using both HLA and non-HLA information in all validation cohorts. This has several implications for risk stratification in CD and other auto-immune diseases. Firstly, the contribution of non-HLA variation for CD risk prediction is unclear, given that previous comparisons were against a baseline that did not make full use of HLA risk variation. [17] Secondly, SNP-based implementation of the $& model is far more parsimonious than models requiring hundreds of SNPs and may be a demonstration of the inability existing regularised machine learning techniques to find the smallest subset of features that yield the best predictive performance, a known issues for some regularized models [31] . Finally, these results may also indicate that HLA genotypes may have been underutilised in construction of GRS for other auto-immune conditions and that further exploration of fine grained HLA data may yield improved risk stratification for other conditions.
Conclusion
This analysis demonstrates that through systematic interpretation of HLA attributed risk, it is possible to improve risk prediction of CD using known and novel HLA risk haplotypes. The Supplementary Tables   Supplementary Table 1 AUCs and significance for all models discussed in the paper across all cohorts. In all cohorts except UK2 (used for training the model), we've indicated which models are not significantly different from the best (the combined HDQ17+GRS228 model). This varies a lot between cohorts both due to model performance as well as the samples size of the different studies. 
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Supplementary Figure 3
To assess whether predictive performance could be further improved through combination of the $& and ++, models, the performance of models variably weighting each predictor were assessed. No significant improvement could be observed over either model using this combination approach. The combination presented in the paper makes use of a 0.9 weighting of HDQ17, meaning the resulting combination reorders the samples within each of the 17 HDQ17 categories by the GRS228.
